Resources

This document provides information for healthcare providers about My Aged Care support plans being available in My Health Record.

The ATAGI 2024 Annual Statement on Immunisation is the fourth publication in this series. The statement highlights the key successes, trends and challenges in the use of vaccines and control of vaccine preventable diseases in Australia in 2023, and includes advice to address key issues for 2024.

This fact sheet contains information for parents and carers on the changes to vaping in Australia.

This fact sheet contains information on the changes to vaping in Australia.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D).

Treating physicians use this application form to apply for a patient to access LSDP medication for Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) for the first time, or after a break.

Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for infantile onset lysosomal acid lipase deficiency (LAL-D) under the Life Saving Drugs Program.

This poster outlines the COVID-19 vaccine doses recommended for each age and population group.

These guidelines contain the general, initial and ongoing eligibility requirements to access asfotase alfa (Strensiq®) for perinatal- and infantile-onset hypophosphatasia under the Life Saving Drugs Program.

Treating physicians use this application form to apply for a patient to access LSDP medication for HPP for the first time, or after a break.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for HPP.

Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.

This document outlines the updates to the LSDP’s testing requirements for Pompe disease, Gaucher disease (type 1), and mucopolysaccharidosis types I, II, and VI arising from the LSDP Expert Panel’s Medicines Reviews Recommendations.

This fact sheet supports care recipients to understand their monthly statement and the responsible use of Home Care Package funds. It accompanies the Care Recipient Guidance – Understanding your Home Care Package statement.

This fact sheet provides advice to health professionals on the changes to Meningococcal ACWY vaccines under the National Immunisation Program (NIP).

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, testing and PPE provided to affected services.

The Statement of Expectations sets out the role for the Aged Care Quality and Safety Commission in preparing the sector for the new Aged Care Act.

This report outlines the evaluation of evidence on the clinical effectiveness of naturopathy supplements as part of the Natural Therapies Review 2024.

These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for Gaucher disease (type 1) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for hereditary tyrosinaemia (type 1) under the Life Saving Drugs Program.